TauRx Reports First Phase 3 Results for LMTX® (y 2)

Publicado 27/07/2016 14:01:54CET

TauRx Therapeutics Ltd is a member of the TauRx Pharmaceuticals group which is developing technology spun-out from the University of Aberdeen, Scotland, and was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company's tau aggregation inhibitor, LMTX(R) targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to 'tau tangles'. TauRx's headquarters are in Singapore and its primary research facilities are based in Aberdeen. For more information, please visit: http://www.taurx.com.

References 


1) Wischik CM, et al. Tau-aggregation inhibitor therapy for Alzheimer's disease.
Biochem Pharmacol 2014;88:529-39.

Email: taurxpress@hkstrategies.com

Website: http://www.taurx.com

Photo:
http://photos.prnewswire.com/prnh/20160727/393315LOGO

CONTACT: Media Contacts: North America: Brian Grancagnolo - +1212.885.0449 / +1 973.432.7950, Europe: Rachel Mackie - +44 207 413 3480 /+44 7584 336 014 , Singapore: Holly Huang - +65 6390 3346 / +65 9880 2082

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación